Personalized Medicine Institute Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 06-07-2024
- Paid Up Capital ₹ 0.50 M
as on 06-07-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 4.71 M
as on 06-07-2024
- Revenue %
(FY 2019)
- Profit -1621.08%
(FY 2019)
- Ebitda -11127.57%
(FY 2019)
- Net Worth -649.43%
(FY 2019)
- Total Assets 103.23%
(FY 2019)
About Personalized Medicine Institute
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.71 M.
Saubhik Sengupta, Nandini Biswas, Saumen Meur, and Three other members serve as directors at the Company.
- CIN/LLPIN
U73100WB2017PTC222284
- Company No.
222284
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Aug 2017
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Personalized Medicine Institute?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Maqsood Siddiqi  | Director | 10-Aug-2017 | Current |
| Nandini Biswas | Director | 10-Aug-2017 | Current |
| Saubhik Sengupta | Additional Director | 12-Mar-2018 | Current |
| Saumen Meur | Director | 10-Aug-2017 | Current |
| Mousumi Sengupta | Director | 10-Aug-2017 | Current |
| Amit Haldar | Director | 10-Aug-2017 | Current |
Financial Performance of Personalized Medicine Institute.
Personalized Medicine Institute Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1621.08% decrease in profit. The company's net worth observed a substantial decline by a decrease of 649.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Personalized Medicine Institute?
In 2019, Personalized Medicine Institute had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Precision Medicine Institute Private LimitedActive 3 years 3 monthsMousumi Sengupta is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 31 May 2018 | ₹4.71 M | Open |
How Many Employees Work at Personalized Medicine Institute?
Unlock and access historical data on people associated with Personalized Medicine Institute, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Personalized Medicine Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Personalized Medicine Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
